ArticlePloS one2026
First-trimester urinary glycolic acid and methylsuccinic acid measurement for preeclampsia prediction: A Systematic review protocol.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPreeclampsia is an important cause of maternal and neonatal morbidity and mortality around the world, with hypertension on the rise in sub-Saharan Africa. First-trimester screening for preeclampsia is vital for guiding preventative therapies like low dose aspirin. Traditional biomarkers face accessibility barriers in low-resource settings. Urinary glycolic acid (GA) and methylsuccinic acid (MSA) have emerged as stable, cost-effective, non-invasive metabolic candidates. However, their prognostic value has not been systematically evaluated. This systematic review aims to evaluate the prognostic value of first trimester urinary glycolic acid and methylsuccinic acid for development of preeclampsia.
methodsThis systematic review will be guided by the Preferred Reporting Items for Systematic Reviews and Meta-Analysis - Protocols (PRISMA-P) checklist and has been registered with PROSPERO (CRD420251057596). The following databases will be searched: Cochrane Library, Embase, PubMed/MEDLINE, Scopus, Web of Science, grey literature and trial registries from 2008 to August 2026. Eligible studies will include pregnant women in the first trimester (<14 weeks) with urinary GA and/or MSA measured, comparing those who develop preeclampsia to normotensive controls. Two independent reviewers will screen titles/abstracts and full texts, with conflicts resolved by a third reviewer. Risk of bias will be assessed using the Quality in Prognosis Studies (QUIPS) tool. Data will be synthesized narratively: if more than 3 studies report comparable metrics, a meta-analysis using a random effects model will be performed. ETHICS AND DISSEMINATION: As a secondary analysis of peer reviewed articles, this review does not require ethical approval. Findings from the review will be disseminated through conference presentations and peer-reviewed publication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.